502841-26-1

Basic information

• Product Name: Pyrrolidine, 3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methyl-1-(phenylmethyl)-, (2S,3S,4S)-
• CAS NO: 502841-26-1
• Molecular Formula: C24H45NO2Si2
• Molecular Weight: 435.798
• Mol File: 502841-26-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Pyrrolidine, 3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methyl-1-(phenylmethyl)-, (2S,3S,4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrrolidine, 3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methyl-1-(phenylmethyl)-, (2S,3S,4S)-(502841-26-1)
• EPA Substance Registry System: Pyrrolidine, 3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-methyl-1-(phenylmethyl)-, (2S,3S,4S)-(502841-26-1)

Safety Data

• Hazardous Substances Data: 502841-26-1(Hazardous Substances Data)

Upstream product

• 136137-86-5 (3R,4R)-3,4-Bis<(tert-butyldimethylsilyl)oxy>-1-benzyl-2,5-pyrrolidinedione 
• 100-46-9 benzylamine 
• 75172-31-5 (3R,4R)-1-benzyl-3,4-dihydroxypyrrolidine-2,5-dione 
• 502841-22-7 (3R,4S,5S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-5-methyl-pyrrolidin-2-one 

Downstream Products

• 162466-21-9 (2S,3S,4S)-1-Benzyl-2-methyl-pyrrolidine-3,4-diol 

Relevant articles and documents

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

Provided are indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which LRRK2 kinase is involved. Also provided are pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Synthesis of pyrrolidine based natural or unnatural product derivatives (1): Application of efficient asymmetric induction of C-2 position in polysubstituted pyrrolidines

A novel method for synthesis of polysubstituted pyrrolidines, which possess a C-2 stereocenter, was developed. The strategy involves Grignard addition to the succinimide, derived from L-tartaric acid, followed by stereocontrolled triethylsilane promoted reduction of the resulting cyclic amidols.